Delcath Systems (NASDAQ:DCTH) Earns Buy Rating from HC Wainwright

Delcath Systems (NASDAQ:DCTH)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 73.09% from the stock’s current price.

Several other research analysts also recently weighed in on DCTH. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. Finally, Stephens reissued a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Delcath Systems Stock Up 0.2 %

Shares of DCTH stock opened at $12.71 on Tuesday. The firm has a market cap of $406.39 million, a P/E ratio of -9.41 and a beta of 0.87. The company has a 50 day moving average of $11.33 and a 200-day moving average of $9.83. Delcath Systems has a 12-month low of $3.70 and a 12-month high of $13.30.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Delcath Systems in the third quarter valued at approximately $102,000. Barclays PLC bought a new position in shares of Delcath Systems in the 3rd quarter worth $104,000. Jane Street Group LLC purchased a new stake in shares of Delcath Systems during the 3rd quarter valued at $110,000. Riverwater Partners LLC bought a new stake in shares of Delcath Systems during the 3rd quarter worth $161,000. Finally, Virtu Financial LLC bought a new stake in shares of Delcath Systems during the 3rd quarter worth $289,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.